Table 2

Frequencies and proportions of outcomes in the ordinal COVID-19 severity scale according to baseline use of biologic or targeted synthetic disease-modifying antirheumatic drug for patients with rheumatoid arthritis at the time of COVID-19 onset (N=2869)

COVID-19 severity scaleOverall
N=2869
n (%)
Abatacept
n=237
n (%)
Rituximab
n=364
n (%)
IL-6 inhibitors
n=317
n (%)
JAK inhibitors
n=563
n (%)
TNF inhibitors
n=1388
n (%)
Not hospitalised2256 (78.6)181 (76.4)210 (57.7)271 (85.5)409 (72.6)1185 (85.4)
Hospitalised without oxygenation137 (4.8)12 (5.1)20 (5.5)13 (4.1)28 (5.0)64 (4.6)
Hospitalised with any oxygen or ventilation319 (11.1)26 (11.0)80 (22.0)24 (7.6)86 (15.3)103 (7.4)
Death157 (5.5)18 (7.6)54 (14.8)9 (2.8)40 (7.1)36 (2.6)
  • IL-6, interleukin 6; JAK, Janus kinase; TNF, tumour necrosis factor.